Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.73 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.73 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6563957 | 0.90 | CXCR2 (0.80) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL2768270 | 0.89 | CXCR2 (0.58) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL6564181 | 0.89 | CXCR2 (0.67) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL6548941 | 0.86 | CXCR2 (0.77) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL6551450 | 0.84 | CXCR2 (1.00) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL6551235 | 0.84 | CXCR2 (0.74) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL4606182 | 0.84 | CXCR2 (0.67) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL30515694 | 0.84 | CXCR2 (1.00) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL29372271 | 0.84 | CXCR2 (1.00) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL1535901 | 0.84 | CXCR2 (1.00) | CXCR2CXCR1CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110954-A1 | Methods of synthesizing phenol-contining compounds | SMITHKLINE BEECHAM CORPORATION | 2004-06-10 | — | — | US | disclosed |
| EP-1161232-B1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-03-24 | — | — | EP | disclosed |
| EP-1383488-A2 | METHODS OF SYNTHESIZING PHENOL-CONTAINING COMPOUNDS | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-06-12 | — | — | US | disclosed |
| US-6500863-B1 | INTERLEUKIN BINDING INHIBITORS SUCH AS N-(2-HYDROXYL-3-AMINO SULFONYL-4-CHLOROPHENYL)-N'-(2-BROMOPHENYL)UREA, USED FOR PROPHYLAXIS OF CHEMOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2002-12-31 | — | — | US | disclosed |
| WO-2002079122-A2 | METHODS OF SYNTHESIZING PHENOL-CONTAINING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-10-10 | — | — | WO | disclosed |
| EP-1161232-A4 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1161232-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000035442-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110954-A1 | Methods of synthesizing phenol-contining compounds | COMT, BPHL, PNMT | CXCR2 2343/4885CXCR1 3658/4885CX3CR1 3931/4885 |
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | CXCL8, CCR8, IL18 | CXCR2 26/4885CXCR1 18/4885CX3CR1 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.